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Fig. 2. Recombinant progranulin (PGRN) attenuated osteoarthritis (OA)
development through the TNFR2 pathway in vivo. (A) Intra-articular
Injection of PGRN dramatically protected cartilage from degeneration
following surgically induced OA model, assayed by Safranin O staining.
Scale bar, 100 mm. (B) Phenotypes of synovium and osteophyte in ACLT
models at 4 weeks treated with PBS and recombinant PGRN protien (a, c)
HE staining of knee Joints samples from ACLT models treated with PBS
and recombinant PGRN protein. Black arrows indicate synovium, and blue
arrow indicates osteophyte formation in PBS treated ACLT model. (b, d)
Magniﬁed ﬁeld of synovium in PBS and PGRN treated groups. Scale bar,
100 mm, (C) Osteoarthritis Research Society International (OARSI) score of
OA, (D) The loss of Aggrecan based on the result of Safranin O staining. (E)
Treatment of PGRN reduced serum level of cartilage oligomeric matrix
protein (COMP) fragments in ACLT model, assayed by ELISA.
Fig. 1. Deﬁciency of progranulin (PGRN) led to exaggerated osteoarthritis
(OA) progression in a surgically induced model. (A) PGRN-deﬁcient mice
exhibited accelerated degeneration of articular cartilage compared with
wild type (WT) littermates, assayed by Safranin O staining. Red arrows
indicated cartilage destruction. Scale bar¼100mm. (B) PGRN deﬁcient mice
dispayed a signiﬁcantly higher score of OA after destabilisation of medial
meniscus (DMM) operation on the basis of Safranin O staining. (C) PGRN-
deﬁcient mice presented a signiﬁcantly higher level of cartilage oligo-
meric matrix protein (COMP) fragment in serum after induction of DMM
model, assayed by ELISA. (D) phenotypes of synovium and osteophyte in
DMM models established in WT and PGRN-deﬁcient mice at 4 weeks.
(a,b) HE staining of knee joints samples from DMM models established in
WT and PGRN-/- mice. Black arrows indicate osteophyte formation. (c, d)
Magniﬁed ﬁeld of osteophyte and synovium in WT and PGRN-deﬁcient
groups. Black arrows indicate osteophyte formation, and blue arrows
indicater synovium, Scale bar¼100mm. (E) immunohistochemistry stain-
ing also showed stronger positive signals for col X, matrix metal-
loproteinase (MMP)13 and COMP fragments in PGRN-deﬁcient group than
WT group 8 weeks after DMM operation. Scale bar¼50mm.
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articular injection of PGRN remarkably protected the structure of
articular cartilage and maintained proteoglycan in the cartilage. Fur-
thermore, As showed in Fig2.B, PGRN treatment dramatically attenu-
ated synovium inﬂammation observed in PBS-treated ACLTgroup ofWT
mice. Moreover, recombinant PGRN treatment exhibited a similar effect
in TNFR1-deﬁcient group, while this protective effect of PGRN was
largely lost when TNFR2 was deﬁcient. Additionally, as illustrated in
Fig.2C and 2D, histological grading analysis showed signiﬁcant
improvement of OA score and attenuation of proteoglycan loss in car-
tilage with treatment of PGRN in WT and TNFR1-deﬁcient mice, but
there was no signiﬁcant change in TNFR2-deﬁcient mice. To further
investigate OA development following treatment of PGRN, sera were
collected from each group, and COMP fragment-speciﬁc ELISA was
performed. As indicated in 2E, treatment of PGRN signiﬁcantly dimin-
ished the levels of COMP fragments in WT and TNFR1-deﬁcient ACLT
model, but not in TNFR2-deﬁcient mice. These results suggest that
PGRN-mediated protection in OA is primarily through the TNFR2
pathway.
Conclusions: PGRN protects against the progression of OA primarily
through TNFR2 signaling pathway. These in vivo studies provide new
insight into the pathogenesis of OA, and also present PGRN as a
potential target for the treatment of joint degenerative diseases,
including OA.
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Purpose: The majority of osteoarthritis (OA) patients show synovial
activation, which is suggested to be involved in joint destruction. Pre-
viously, we found increased expression of various members of the Wnt
signaling pathway in the synovium in two experimental OA mouse
models. In addition, we found that expression of WISP1, a key down-
stream target of the canonical Wnt signaling, was signiﬁcantly elevated
in the synovium and cartilage in experimental OAmodels and in human
OA cartilage. However, the role of WISP1 in the initiation and pro-
gression of OA is not known. In the present study, we investigated the
role ofWISP1 during OA by inducing various experimental OAmodels in
WISP1 KO mice. In addition, we determined if WISP1 was involved in
the progression of early OA in humans.
Methods: Pathway analysis of microarray data from the synovium of
both a collagenase-induced OA (CIOA) and a destabilization of the
medial meniscus (DMM) mouse model was performed using DAVID.
Microarray analysis was performed on the synovial tissue of patients
enrolled in the CHECK study. This cohort study is a multicenter based
initiative of the Dutch Arthritis Foundation to follow the progression of
OA symptoms in patients that visited their general practitioner with
early complaints of knee or hip pain. Expression data was correlated
with damage at baseline and progression of OA between baseline and
the ﬁve-year follow-up measurement. Progression was deﬁned as a
decrease in joint space width of at least 1 mm and progression of
osteophyte formation of at least 4x in size. Experimental OA was
induced in WT and WISP1 KO mice. Joint pathology was assessed by
histology. Human OA synovium was obtained after joint replacement
surgery and stimulated with WISP1. Smad phosphorylation and b-cat-
enin accumulation were determined using immunohistochemistry.
Results: Pathway analysis of microarray data from synovial tissue
showed enrichment of the Wnt signaling pathway in both the CIOA and
DMM at various time points after induction. In addition, microarray
analysis of synovial tissue obtained from patients in the CHECK cohort
of early OA patients showed a correlation between WISP1 expression
and damage at baseline. Moreover, WISP1 expression levels were cor-
related with the progression of OA between baseline and the ﬁve-year
follow-up measurement. In order to further pinpoint the role of WISP1
in the etiopathology of OA, we induced experimental OA in WT and
WISP1 KO mice. After the development of OA pathology, we found
signiﬁcantly decreased cartilage damage in the tibio-femoral joints of
theWISP1 KOmice as compared with theWTmice. Synovium ofWISP1
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our ﬁnding that stimulation of human OA synovium with WISP1 led to
increased MMP expression. TGF-b signaling via Smad 2/3 is crucial for
maintaining the homeostasis of the cartilage, while signaling via Smad
1/5/8 is associated with chondrocyte hypertrophy. In order to deter-
mine if WISP1 affects TGF-b signaling, we stained WT and WISP1
depleted joints for phosphorylated Smad 2/3. We found that Smad 2/3
signaling was increased in the WISP1 KO mice, suggesting that
increasedWISP1 expression during OA decreases Smad 2/3 signaling. In
addition, recent data showed that WISP1 might not only act as a
downstream target of canonical Wnt signaling, but could also regulate
the accumulation of b-catenin, and positively control canonical Wnt
signaling, further aggravating the OA pathology. To investigate if this
mechanismwas present in experimental OA, we stained our sections for
b-catenin and found thatWISP1 depleted tissues indeed have decreased
levels of b-catenin accumulation in the cartilage.
Conclusions: Overexpression of WISP1 in the synovium and cartilage,
as is found in OA conditions, may play an important role in OA path-
ology via modulation of TGF-b signaling and via a positive feedback
mechanism on canonical Wnt signaling. Because Wnt signaling is both
extremely complex and tightly regulated and can affect many biological
processes, upstream targeting of Wnt signaling is likely to produce
undesired side-effects. Speciﬁc downregulation of WISP1 may more
speciﬁcally target the pathological events that take place during OA
without interfering with normal processes.
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Purpose: Several population studies have found an association between
increased body mass index (BMI), as a measure of obesity, and higher
disc degeneration scores and that the effect of obesity upon back pain is
mediated by greater disc degeneration. However, other pathological
changes to the disc and spinal column, in particular disc herniation and
spinal stenosis, are associated with speciﬁc clinical conditions; whether
these pathological changes are also inﬂuenced by obesity is unclear.
Here we examine the relationships between BMI and MRI measures of
intervertebral disc degeneration (DD), disc herniation (DH) and spinal
stenosis (SS), using a large prospectively recruited patient population.
Methods: Patients were recruited from tertiary spine centres in 4 EU
countries. An experienced radiologist scored T1 and T2 magnetic res-
onance images (MRI) images for DD (Pﬁrrmann grading system), any
DH (size and presence) or any SS (presence and severity). Multivariate
linear and logistic regression analyses were used to model the rela-
tionship between these variables and BMI. Given the comprehensive
data collection, we were able to adjust for both patient (age, gender,
sporting activity, smoking, occupation and comorbidities) and MRI
deﬁned (Modic changes, end plate sclerosis and end plate defects)
confounders.
Results: The analysis included 1684 patients with a mean age of 51
years and BMI of 27.2kg/m2. The relationship between age and DD
(r¼0.66) was considerably stronger than that for BMI and DD (r¼0.17)
(Figure a & b). Lumbar disc degeneration and disc herniation were
both more marked at lower spinal levels with L5/S1 showing the
highest DD and greatest prevalence of DH. In the fully adjusted model,
a 10-year increase in age and a 5kg/m2 increase in BMI were asso-
ciated with a 0.31 unit [CI 0.29,0.34] and 0.04 unit [CI 0.01,0.07]
increase in degeneration, respectively. BMI was not associated with
severe (grade 5) DD (OR 1.06 [CI 0.94,1.20]) or multilevel DD (OR 1.12
[CI 0.96,1.30]). All end plate features were associated with more severe
degeneration. Age (OR 2.60 [CI 2.28,2.96]) and BMI (OR 1.23 [CI
1.06,1.43]) were also positively associated with the presence of
stenosis. BMI was also a positive predictor of multilevel stenosis (OR
1.18 [CI 1.00,1.39]) but not severe stenosis (OR 1.11 [CI 0.92,1.35]). In
contrast, BMI was not a predictor of multilevel herniation (OR 1.14 [CI
0.97,1.35]) but was for severe herniation (OR 1.13 [CI 1.01,1.27]). For DHpresence, age was a negative predictor (OR 0.70 [CI 0.64,0.76]) but BMI
(OR 1.19 [CI 1.07,1.33]) showed a strong positive association. There
were no other signiﬁcant predictors of either DH or SS. When the
upper lumbar spine was considered separately, BMI was the strongest
predictor for disc herniation (OR 1.39 [CI 1.10,1.77]) and spinal stenosis
(OR 1.65 [CI 1.27,2.16]).
Conclusions: An increase in disc degeneration was most strongly
associated with increasing age. Increasing age was also a strong pre-
dictor of spinal stenosis and, after mid-life, a negative predictor for disc
herniation. Higher body mass index was associated with greater disc
degeneration but the small coefﬁcient suggests limited clinical rele-
vance. The upper lumbar discs appear more sensitive to increased BMI,
supporting the upper lumbar spine phenotype described by others.
Abnormal loading in obesity could be a mediator of this. For disc her-
niation and spinal stenosis, BMI is a more clinically meaningful positive
predictor than for disc degeneration. We now need to understand how
obesity predisposes to DH and SS and if weight loss can help prevent
these conditions.
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Purpose: OA and associated joint pain is a major cause of disability,
and there is a high unmet need for effective and safe analgesic
therapies. Substantial pain alleviation has been reported for OA
patients treated with intravenous (IV) infusions of antibodies which
block nerve growth factor (NGF), however an increased drug-related
risk for accelerated OA progression was observed in some patients. As
an alternate strategy for targeting this pathway, we identiﬁed a novel
small molecule compound, GZ389988, as an inhibitor of TrkA, the
high-afﬁnity receptor for NGF. GZ389988 was formulated for intra-
articular (IA) delivery, and its effects on local knee pain were tested in
rats using both a monosodium iodoacetate (MIA) induced model of OA,
as well as an arthritis ﬂare model mediated by streptococcal pepti-
doglycan polysaccharide (PGPS).
Methods: Identiﬁcation of TrkA inhibitor GZ389988: Drug candidate
screening was conducted to select inhibitors of Trk family tyrosine
kinases. Low solubility compounds were evaluated using a cell-based
TrkA assay, and further screened against kinase and safety/liability
panels. Acute cytotoxicity was assessed by neutral red assay for a variety
of cell types, including primary human chondrocytes and synoviocytes
(Articular Engineering). In vivo biocompatibility was tested by IA
injection of GZ389988 into rat knee joints.
Preclinical rat OA model: Unilateral knee OA was initiated by IA
injection of MIA. One week later, diseased (ipsilateral) joints were
treated with a single IA injection of GZ389988 or placebo/vehicle, and
differences in hind-limb weight distribution were measured weekly
for 4 weeks by incapacitance testing. In some cases, GZ389988 was
administered to the contralateral knee instead, to test for the occur-
rence of systemic compound distribution affecting the ipsilateral
joint.
Preclinical rat arthritis ﬂaremodel (Bolder BioPATH): Unilateral primary
knee arthritis was induced by IA injection of PGPS. Two weeks later,
animals received a single IA injection of GZ389988 or placebo/vehicle
into the diseased (ipsilateral) joint. Disease reactivation ﬂares were
triggered by IV administration of PGPS at weeks 1 and 3 following drug
(or placebo) treatment. Gait analysis was conducted by obtaining inked
pawprint impressions from animals which were allowed to ambulate
